Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. (ARWR) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
arwr · pe ratio · data through Sep 30, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Arrowhead Pharmaceuticals, Inc. (ARWR) measures how much investors pay for each dollar of the company's trailing earnings. ARWR's current PE ratio of N/A is calculated by dividing its stock price of $73.47 by its TTM earnings per share of -$2.11.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-09-30
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Arrowhead Pharmaceuticals, Inc.You ARWR | $10.3B | N/A | — | -$2.11 |
 Arcellx, Inc. ACLX | $6.7B | N/A | — | -$4.07 |
 Alkermes plc ALKS | $7.1B | 19.07x | -29.3% | $1.47 |
 Axsome Therapeutics, Inc. AXSM | $12.2B | N/A | — | -$3.68 |
 CRISPR Therapeutics AG CRSP | $5.0B | N/A | — | -$6.47 |
 Krystal Biotech, Inc. KRYS | $8.9B | 34.84x | +29.3% | $7.08 |
 Kymera Therapeutics, Inc. KYMR | $6.1B | N/A | — | -$3.69 |
Industry Average 2 peers with valid PE | — | 26.95x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-09-30Latest FY2025 | — | $-0.01 | — | |
2024-09-30 FY2024 | — | $-5.00 | — | |
2023-09-30 FY2023 | — | $-1.91 | — | |
2022-09-30 FY2022 | — | $-1.67 | — | |
2021-09-30 FY2021 | — | $-1.36 | — | |
2020-09-30 FY2020 | — | $-0.84 | — | |
2019-09-30 FY2019 | 38.91x | $0.72 | — | |
2018-09-30 FY2018 | — | $-0.65 | — | |
2017-09-30 FY2017 | — | $-0.47 | — | |
2016-09-30 FY2016 | — | $-1.34 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Arrowhead Pharmaceuticals, Inc. (ARWR) measures how much investors pay for each dollar of the company's trailing earnings. ARWR's current PE ratio of N/A is calculated by dividing its stock price of $73.47 by its TTM earnings per share of -$2.11.
Frequently asked questions
ARWR pe ratio · 6 questionsARWR's current PE ratio is N/A as of 2026-06-08, based on a stock price of $73.47 and TTM EPS of -$2.11. Data sourced from Financial Modeling Prep via ARWR's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Arrowhead Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08